Aldeyra Therapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
Aldeyra Therapeutics (ALDX), a biotechnology company focused on developing therapies for immune-mediated and metabolic diseases, has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference. The virtual event will feature a fireside chat with Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, and Francois Brisebois, Managing Director and Senior Biotech Research Analyst.
The discussion is scheduled for February 11, 2025, at 9:20 a.m. ET. Investors can access the live webcast through the Investors & Media section of Aldeyra's website. The recorded session will remain available for 90 days following the event.
Aldeyra Therapeutics (ALDX), una compagnia biotecnologica dedicata allo sviluppo di terapie per malattie di origine immunitaria e metaboliche, ha annunciato la sua partecipazione alla 35ª Conferenza Annuale sulle Scienze della Vita di Oppenheimer. L'evento virtuale includerà una conversazione informale con Todd C. Brady, M.D., Ph.D., Presidente e CEO di Aldeyra, e Francois Brisebois, Direttore Generale e Analista Senior di Ricerca Biotech.
La discussione è programmata per l'11 febbraio 2025, alle 9:20 a.m. ET. Gli investitori possono accedere alla diretta streaming attraverso la sezione Investitori & Media del sito web di Aldeyra. La registrazione della sessione rimarrà disponibile per 90 giorni dopo l'evento.
Aldeyra Therapeutics (ALDX), una compañía de biotecnología centrada en el desarrollo de terapias para enfermedades mediadas por el sistema inmune y metabólicas, ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer. El evento virtual contará con una charla informal entre Todd C. Brady, M.D., Ph.D., Presidente y CEO de Aldeyra, y Francois Brisebois, Director General y Analista de Investigación Biofarmacéutica Senior.
La discusión está programada para el 11 de febrero de 2025, a las 9:20 a.m. ET. Los inversores pueden acceder a la transmisión en vivo a través de la sección de Inversores y Medios en el sitio web de Aldeyra. La sesión grabada estará disponible durante 90 días después del evento.
Aldeyra Therapeutics (ALDX)는 면역 매개 및 신진대사 질환을 위한 치료제를 개발하는 생명공학 회사로, Oppenheimer의 제35회 연례 헬스케어 생명 과학 컨퍼런스에 참여한다고 발표했습니다. 이 가상 이벤트에서는 Todd C. Brady, M.D., Ph.D., Aldeyra의 사장 겸 CEO와 Francois Brisebois, 매니징 디렉터 겸 선임 생명공학 연구 분석가와의 대담이 진행됩니다.
토론은 2025년 2월 11일 오전 9시 20분 ET에 예정되어 있습니다. 투자자들은 Aldeyra 웹사이트의 투자자 및 미디어 섹션을 통해 실시간 웹캐스트에 접속할 수 있습니다. 녹화된 세션은 이벤트 후 90일 동안 이용 가능합니다.
Aldeyra Therapeutics (ALDX), une société de biotechnologie axée sur le développement de thérapies pour les maladies immunitaires et métaboliques, a annoncé sa participation à la 35e Conférence Annuelle sur les Sciences de la Vie d'Oppenheimer. L'événement virtuel inclura une discussion informelle avec Todd C. Brady, M.D., Ph.D., Président et CEO d'Aldeyra, et Francois Brisebois, Directeur Général et Analyste Senior en Recherche Biotechnologique.
La discussion est prévue pour le 11 février 2025, à 9h20 ET. Les investisseurs peuvent accéder à la diffusion en direct via la section Investisseurs & Médias du site web d'Aldeyra. La session enregistrée restera accessible pendant 90 jours après l'événement.
Aldeyra Therapeutics (ALDX), ein Biotechnologieunternehmen, das sich auf die Entwicklung von Therapien für immunvermittelte und Stoffwechselerkrankungen konzentriert, hat seine Teilnahme an der 35. Jahreskonferenz für Gesundheits- und Lebenswissenschaften von Oppenheimer angekündigt. Die virtuelle Veranstaltung wird ein informelles Gespräch mit Todd C. Brady, M.D., Ph.D., Präsident und CEO von Aldeyra, und Francois Brisebois, Managing Director und Senior Biotech Research Analyst, beinhalten.
Die Diskussion ist für den 11. Februar 2025, um 9:20 Uhr ET angesetzt. Investoren können über den Bereich Investoren & Medien auf der Website von Aldeyra auf das Live-Webcast zugreifen. Die aufgezeichnete Sitzung wird 90 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
Dr. Brady’s conversation with Francois Brisebois, Managing Director, Senior Biotech Research Analyst, is scheduled to begin at 9:20 a.m. ET Tuesday, February 11, 2025. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. Following the fireside chat, the webcast will be archived for 90 days.
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204881772/en/
Investor & Media Contact:
Laura Nichols
Tel: (781) 257-3060
investorrelations@aldeyra.com
Source: Aldeyra Therapeutics, Inc.
FAQ
When is Aldeyra Therapeutics (ALDX) presenting at Oppenheimer's Healthcare Conference?
How can investors watch ALDX's presentation at the Oppenheimer Conference?
How long will ALDX's Oppenheimer Conference presentation be available for replay?
What type of presentation will ALDX give at the Oppenheimer Healthcare Conference?
